Biologics in asthma: Difficulties and drawbacks

Expert Opinion on Biological Therapy

Volumn 8, Issue 12, 2008, Pages 1921-1928

  Bousquet, Jean ^a,b   Chiron, Raphael ^a   Humbert, Marc ^c  

^a HÔPITAL ARNAUD DE VILLENEUVE   (France)

^b INSERM   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Asthma; Biologics; Control; Costs; Omalizumab; Side effects

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; CETUXIMAB; CORTICOSTEROID; DACLIZUMAB; ETANERCEPT; GOLIMUMAB; IMMUNOGLOBULIN E ANTIBODY; INFLIXIMAB; INTERLEUKIN 4 ANTIBODY; INTERLEUKIN 5 ANTIBODY; KELIXIMAB; MEPOLIZUMAB; OMALIZUMAB; PITRAKINRA; PLACEBO; UNCLASSIFIED DRUG;

ANAPHYLAXIS; ANTIGEN EXPRESSION; ASTHMA; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; CROHN DISEASE; DOWN REGULATION; DRUG COST; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; EOSINOPHILIA; HUMAN; INFECTION; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; QUALITY OF LIFE; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; SIDE EFFECT; SKIN MANIFESTATION; T LYMPHOCYTE ACTIVATION; TREATMENT FAILURE;

ANIMALS; ANTIBODIES, MONOCLONAL; ASTHMA; BIOLOGICAL PRODUCTS; COSTS AND COST ANALYSIS; HUMANS; HYPERSENSITIVITY;

EID: 57649186608     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712590802496928     Document Type: Review

References (62)

1. Lonberg N. Human monoclonal antibodies from transgenic mice. Handb Exp Pharmacol 2008;181:69-97
2. Nissim A, Chernajovsky Y. Historical development of monoclonal antibody therapeutics. Handb Exp Pharmacol 2008;181:3-18
3. MacGlashan D. Loss of receptors and IgE in vivo during treatment with anti-IgE antibody. J Allergy Clin Immunol 2004;114(6):1472-4
4. Beck LA, Marcotte GV, MacGlashan D, et al. Omalizumab-induced reductions in mast cell Fc RI expression and function. J Allergy Clin Immunol 2004;114(3):527-30
5. Holgate S, Casale T, Wenzel S, et al. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol 2005;115(3):459-65
6. Djukanovic R, Wilson SJ, Kraft M, et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 2004;170(6):583-93
7. Fahy JV. Anti-IgE. lessons learned from effects on airway inflammation and asthma exacerbation. J Allergy Clin Immunol 2006;117(6):1230-2
8. Holgate ST, Djukanovic R, Casale T, Bousquet J. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy. Clin Exp Allergy 2005;35(4):408-16
9. Bousquet J, Cabrera P, Berkman N, et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005;60(3):302-8
10. Bousquet J, Rabe K, Humbert M, et al. Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respir Med 2007;101(7):1483-92
11. Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005;60(3):309-16
12. Kon OM, Sihra BS, Loh LC, et al. The effects of an anti-CD4 monoclonal antibody, keliximab, on peripheral blood CD4+ T-cells in asthma. Eur Respir J 2001;18(1):45-52
13. Kon OM, Sihra BS, Compton CH, et al. Randomised, dose-ranging, placebo-controlled study of chimeric antibody to CD4 (keliximab) in chronic severe asthma. Lancet 1998;352(9134):1109-13
14. Simon D, Braathen LR, Simon HU. Anti-interleukin-5 antibody therapy in eosinophilic diseases. Pathobiology 2005;72(6):287-92
15. Pauwels RA, Brusselle GJ, Kips JC. Cytokine manipulation in animal models of asthma. Am J Respir Crit Care Med 1997;156(4 Pt 2):S78-81
16. Leckie MJ, Ten Brinke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000;356(9248):2144-8
17. Flood-Page P, Swenson C, Faiferman I, et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 2007;176(11):1062-71
18. Rosenberg HF, Phipps S, Foster PS. Eosinophil trafficking in allergy and asthma. J Allergy Clin Immunol 2007;119(6):1303-10; quiz 1311-2
19. O'Byrne PM. The demise of anti IL-5 for asthma, or not. Am J Respir Crit Care Med 2007;176(11):1059-60
20. Van Rensen EL, Stirling RG, Scheerens J, et al. Evidence for systemic rather than pulmonary effects of interleukin-5 administration in asthma. Thorax 2001;56(12):935-40
21. Flood-Page P, Menzies-Gow A, Phipps S, et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest 2003;112(7):1029-36
22. Plotz SG, Simon HU, Darsow U, et al. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med 2003;349(24):2334-9
23. Gevaert P, Lang-Loidolt D, Lackner A, et al. Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. J Allergy Clin Immunol 2006;118(5):1133-41
24. Borish LC, Nelson HS, Corren J, et al. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol 2001;107(6):963-70
25. Borish LC, Nelson HS, Lanz MJ, et al. Interleukin-4 receptor in moderate atopic asthma. A Phase I/II randomized, placebo-controlled trial. Am J Respir Crit Care Med 1999;160(6):1816-23
26. Wenzel S, Wilbraham D, Fuller R, et al. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 2007;370(9596):1422-31
27. Heffler E, Berry M, Pavord ID. Tumor necrosis factor-α: a promising therapeutic target for asthma? BioDrugs 2007;21(6):345-9
28. Berry MA, Hargadon B, Shelley M, et al. Evidence of a role of tumor necrosis factor α in refractory asthma. N Engl J Med 2006; 354(7):697-708
29. Howarth PH, Babu KS, Arshad HS, et al. Tumour necrosis factor (TNFα) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax 2005;60(12):1012-8
30. Casale TB, Stokes JR. Immunomodulators for allergic respiratory disorders. J Allergy Clin Immunol 2008;121(2):288-96; quiz 297-8
31. Schaafsma D, Gosens R, Zaagsma J, et al. Rho kinase inhibitors: a novel therapeutical intervention in asthma? Eur J Pharmacol 2008;585(2-3):398-406
32. Pichler WJ. Adverse side-effects to biological agents. Allergy 2006;61(8):912-20
33. Georgitis JW, Browning MC, Steiner D, Lorentz WB. Anaphylaxis and desensitization to the murine monoclonal antibody used for renal graft rejection. Ann Allergy 1991;66(4):343-7
34. Cheifetz A, Mayer L. Monoclonal antibodies, immunogenicity, and associated infusion reactions. Mt Sinai J Med 2005;72(4):250-6
35. Campi P, Benucci M, Manfredi M, Demoly P. Hypersensitivity reactions to biological agents with special emphasis on tumor necrosis factor-α antagonists. Curr Opin Allergy Clin Immunol 2007;7(5):393-403
36. Kolho KL, Ruuska T, Savilahti E. Severe adverse reactions to Infliximab therapy are common in young children with inflammatory bowel disease. Acta Paediatr 2007;96(1):128-30
37. Dore RK, Mathews S, Schechtman J, et al. The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis. Clin Exp Rheumatol 2007;25(1):40-6
38. Weinblatt ME, Keystone EC, Furst DE, et al. Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. Ann Rheum Dis 2006;65(6):753-9
39. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48(1):35-45
40. Zeltser R, Valle L, Tanck C, et al. Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor α receptor: Fc fusion protein. Arch Dermatol 2001;137(7):893-9
41. Winfield H, Lain E, Horn T, Hoskyn J. Eosinophilic cellulitis-like reaction to subcutaneous etanercept injection. Arch Dermatol 2006;142(2):218-20
42. Benucci M, Manfredi M, Demoly P, Campi P. Injection site reactions to TNF-α blocking agents with positive skin tests. Allergy 2008; 63(1):138-9
43. Youdim A, Vasiliauskas EA, Targan SR, et al. A pilot study of adalimumab in infliximab-allergic patients. Inflamm Bowel Dis 2004;10(4):333-8
44. Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist 2007;12(5):601-9
45. Patel DD, Goldberg RM. Cetuximab-associated infusion reactions: pathology and management. Oncology (Williston Park) 2006;20(11):1373-82; discussion 1382, 1392-4, 1397
46. O'Neil BH, Allen R, Spigel DR, et al. High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. J Clin Oncol 2007;25(24):3644-8
47. Chung CH, Mirakhur B, Chan E, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-α-1,3-galactose. N Engl J Med 2008;358(11):1109-17
48. Limb SL, Starke PR, Lee CE, Chowdhury BA. Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma. J Allergy Clin Immunol 2007;120(6):1378-81
49. Cox L, Platts-Mills TA, Finegold I, et al. American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis. J Allergy Clin Immunol 2007;120(6):1373-7
50. Sampson HA, Munoz-Furlong A, Bock SA, et al. Symposium on the definition and management of anaphylaxis: summary report. J Allergy Clin Immunol 2005;115(3):584-91
51. Rutgeerts P, Van Assche G, Vermeire S. Review article: Infliximab therapy for inflammatory bowel disease-seven years on. Aliment Pharmacol Ther 2006;23(4):451-63
52. Pilette C, Coppens N, Houssiau FA, Rodenstein DO. Severe serum sickness-like syndrome after omalizumab therapy for asthma. J Allergy Clin Immunol 2007;120(4):972-3
53. Cruz AA, Lima F, Sarinho E, et al. Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection. Clin Exp Allergy 2007;37(2):197-207
54. Bendtzen K, Geborek P, Svenson M, et al. Individualized monitoring of drug - bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor α inhibitor infliximab. Arthritis Rheum 2006;54(12):3782-9
55. Svenson M, Geborek P, Saxne T, Bendtzen K. Monitoring patients treated with anti-TNF-α biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. Rheumatology (Oxford) 2007;46(12):1828-34
56. Peyrin-Biroulet L, Laclotte C, Bigard MA. Adalimumab maintenance therapy for Crohn's disease with intolerance or lost response to infliximab: an open-label study. Aliment Pharmacol Ther 2007;25(6):675-80
57. Peyrin-Biroulet L, Laclotte C, Roblin X, Bigard MA. Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: an open-label study. World J Gastroenterol 2007;13(16):2328-32
58. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007;357(3):239-50
59. Brown R, Turk F, Dale P, Bousquet J. Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma. Allergy 2007;62(2):149-53
60. Dewilde S, Turk F, Tambour M, Sandstrom T. The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of INNOVATE to Sweden. Curr Med Res Opin 2006;22(9):1765-76
61. Krishnan JA, Gould M. Omalizumab for severe allergic asthma: dollars and sense. J Allergy Clin Immunol 2007;120(5):1015-7
62. Wu AC, Paltiel AD, Kuntz KM, et al. Cost-effectiveness of omalizumab in adults with severe asthma results from the Asthma Policy Model. J Allergy Clin Immunol 2007;120(5):1146-52